Title

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
The Effect of Seminal Fluid on Distal Colon Mucosal Permeability and Susceptibility to HIV Infection
  • Phase

    N/A
  • Study Type

    Interventional
  • Study Participants

    11
This research is being done to learn how seminal fluid affects the lining of the colon, and whether this might make it easier for HIV to get into the body and cause infection.
Design of effective rectal microbicides to prevent HIV infection requires an understanding of rectal HIV transmission and the location within the lower gastrointestinal (GI) tract (luminal and mucosal) of HIV (cell-free and cell-associated) following exposure to infected seminal fluid. These basic details of HIV transmission have yet to be determined in human subjects, yet they are essential to select microbicide candidates if they are to be rationally designed to achieve effective concentrations at sites of HIV transmission. Rational development of a rectal microbicide also requires an understanding of those factors that may contribute to colonic mucosal injury - potential confounders of microbicidal effect. Such factors include exposure to seminal fluid which has been shown in animal and in vitro studies to cause histologic and permeability changes that might facilitate HIV transmission.
Study Started
Mar 31
2008
Primary Completion
Dec 31
2009
Study Completion
Dec 31
2009
Results Posted
May 25
2017
Last Update
May 25
2017

Biological Radiolabeled autologous seminal fluid

Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.

Biological Radiolabeled Normosol-R

Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.

Seminal Fluid then Normosol Experimental

2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.

Normosol then Seminal Fluid Experimental

2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.

Criteria

Inclusion Criteria:

Able to provide signed informed consent
Men of 21 years or older.
Prior history of receptive anal intercourse.
Laboratory values within the last 28 days:
Negative for HIV antibodies
Lymphocyte count within normal limits
Neutrophil count > 1,000 cells/ml
Cluster of Differentiation 4 (CD4) cell count > 500 cells/ml
Platelet count ≥ 150,000 cells/mm3
Prothrombin Time (PT) within normal limits
Partial thromboplastin time (PTT) within normal limits.
No childbearing intentions.

Exclusion Criteria:

Active anorectal disease or recent (3 months) anorectal surgery;
Diarrhea, defined as three or more loose stools per day, for at least three days prior to admission.
History of sleep apnea, or airway problems with previous sedation procedures.
History of significant adverse reaction to sedation medications.
Other history, including significant occupational radiation exposure, history of inflammatory bowel disease or any other diseases and lab results, such that, in the judgment of the investigator, study procedures are not considered safe for the subject's participation.

Summary

Seminal Fluid

Normosol-R

All Events

Event Type Organ System Event Term Seminal Fluid Normosol-R

Epithelial Disruption Graded by a Pathologist Blinded to Study Intervention.

Endoscopy will be performed to obtain biopsy specimens at baseline and following each inpatient enema exposure. Samples will be obtained at each flexible sigmoidoscopy and set aside for batch sectioning and H&E staining. Slides will be reviewed and scored by a qualified pathologist blinded to treatment assignment using a qualitative scoring system. This scoring system uses semi-quantitative scoring that focuses on acute toxicity to epithelial cell layer similar to that seen in animal studies. This is a categorical grading scale, where 0 = Epithelial surface intact;1 = <1/3 of surface denuded; 2 = 1/3 - 2/3rds of surface denuded;3 = More than 2/3rds of surface denuded. Six separate biopsies for each subject and each treatment intervention were analyzed in a multi-level analysis. In comparison with the baseline condition (no intervention), the odds and 95% confidence interval (CI) of having a higher epithelial denudation score were calculated for each intervention.

Seminal Fluid

1.0
units on a scale (Median)
Inter-Quartile Range: 0.92 to 1.17

Normosol-R

1.17
units on a scale (Median)
Inter-Quartile Range: 1.04 to 1.46

Total

10
Participants

Age, Continuous

41.5
years (Median)
Full Range: 21.0 to 50.0

Region of Enrollment

Sex/Gender, Customized

1st Intervention

Seminal Fluid, Then Normosol-R

Normosol-R Then Seminal Fluid

14 Day Washout

Seminal Fluid, Then Normosol-R

Normosol-R Then Seminal Fluid

2nd Study Intervention

Seminal Fluid, Then Normosol-R

Normosol-R Then Seminal Fluid

Drop/Withdrawal Reasons

Normosol-R Then Seminal Fluid